Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis
et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 (meta analysis)
Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients:All studies: RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I2: 42%
RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10%The RCT result is non-significant, but is highly affected by the very late stage RECOVERY trial, which is not generalizable to earlier usage.Currently there are 33 colchicine for COVID-19 studies, showing 39% [26‑51%] lower mortality, 43% [-6‑69%] lower ventilation, 29% [6‑46%] lower ICU admission, 23% [14‑31%] lower hospitalization, and 73% [-4‑211%] higher cases.
RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10%The RCT result is non-significant, but is highly affected by the very late stage RECOVERY trial, which is not generalizable to earlier usage.Currently there are 33 colchicine for COVID-19 studies, showing 39% [26‑51%] lower mortality, 43% [-6‑69%] lower ventilation, 29% [6‑46%] lower ICU admission, 23% [14‑31%] lower hospitalization, and 73% [-4‑211%] higher cases.
Zein et al., 1/12/2022, peer-reviewed, 2 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.